GlassScriptPhysician profile
David L Stern
NPI 1487979837
$50,061.59
in general payments reported to CMS, 2019-2025
11 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,293 · 2021: $2,100 · 2022: $2,813 · 2023: $3,564 · 2024: $2,718 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Food and Beverage: $2,063 · Travel and Lodging: $1,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,735.00 |
| Food and Beverage | $2,063.42 |
| Travel and Lodging | $1,894.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $19,640.93 | 2019-2025 | Amvuttra |
| Bridgebio Pharma, INC. | $12,024.90 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $9,230.03 | 2022-2025 | Wainua |
| Pfizer INC. | $7,965.45 | 2019-2025 | |
| Boston Scientific Corporation | $614.29 | 2019-2024 | Watchman Flx, Emblem Mri S-Icd |
| Atricure, INC. | $312.42 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Sanofi-Aventis U.S. LLC | $125.00 | 2019 | |
| Medtronic, INC. | $92.61 | 2025 | Aurora Ev-Icd Mri Surescan |
| Novartis Pharmaceuticals Corporation | $42.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.46 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.